Name: Poziotinib ( HM781-36B)
CAS#: 1092364-38-9
Chemical Formula: C23H21Cl2FN4O3
Exact Mass: 490.09747
Molecular Weight: 491.34
Elemental Analysis: C, 56.22; H, 4.31; Cl, 14.43; F, 3.87; N, 11.40; O, 9.77
We produce Poziotinib ( HM781-36B),1092364-38-9 in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Poziotinib ( HM781-36B),1092364-38-9 Intermediates, we have 8; Poziotinib ( HM781-36B),1092364-38-9 Impurity we have 10, all from GMP, FDA plant.
Now Poziotinib ( HM781-36B),1092364-38-9 DMF document is preparing.
Until 2016, Aug, Poziotinib ( HM781-36B),1092364-38-9 more than produced 25kg API, 120kg Intermediates
Poziotinib HM-781-36; HM-781-36B; NOV-1201;NOV-120101 1092364-38-9
Poziotinib Intermediates 3,4-Dihydro-7-methoxy-4-oxoquinazolin-6-yl acetate 179688-53-0
Poziotinib Intermediates 4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-ol 1429757-65-2
Description: Poziotinib , also known as HM781-36B and NOV120101, is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity. HM781-36B irreversibly inhibits EGFR (HER1 or ErbB1), including EGFR mutants, HER2, and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. EGFRs, cell surface receptor tyrosine kinases, are often upregulated in a variety of cancer cell types and play key roles in cellular proliferation and survival.
Synonym: HM781-36B; HM78136B; HM-78136B; HM 78136B; NOV120101; NOV-120101; NOV 120101; Poziotinib
IUPAC/Chemical Name: 1-(4-((4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
SMILES Code: C=CC(N1CCC(OC2=CC3=C(NC4=CC=C(Cl)C(Cl)=C4F)N=CN=C3C=C2OC)CC1)=O
1: Cha MY, Lee KO, Kim M, Song JY, Lee KH, Park J, Chae YJ, Kim YH, Suh KH, Lee GS, Park SB, Kim MS. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012 May 15;130(10):2445-54. doi: 10.1002/ijc.26276. Epub 2011 Aug 24. PubMed PMID: 21732342.
2: Nam HJ, Kim HP, Yoon YK, Hur HS, Song SH, Kim MS, Lee GS, Han SW, Im SA, Kim TY, Oh DY, Bang YJ. Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Lett. 2011 Mar 28;302(2):155-65. PubMed PMID: 21306821.
CAS#: 1092364-38-9
Chemical Formula: C23H21Cl2FN4O3
Exact Mass: 490.09747
Molecular Weight: 491.34
Elemental Analysis: C, 56.22; H, 4.31; Cl, 14.43; F, 3.87; N, 11.40; O, 9.77
We produce Poziotinib ( HM781-36B),1092364-38-9 in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Poziotinib ( HM781-36B),1092364-38-9 Intermediates, we have 8; Poziotinib ( HM781-36B),1092364-38-9 Impurity we have 10, all from GMP, FDA plant.
Now Poziotinib ( HM781-36B),1092364-38-9 DMF document is preparing.
Until 2016, Aug, Poziotinib ( HM781-36B),1092364-38-9 more than produced 25kg API, 120kg Intermediates
Poziotinib HM-781-36; HM-781-36B; NOV-1201;NOV-120101 1092364-38-9
Poziotinib Intermediates 3,4-Dihydro-7-methoxy-4-oxoquinazolin-6-yl acetate 179688-53-0
Poziotinib Intermediates 4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-ol 1429757-65-2
Description: Poziotinib , also known as HM781-36B and NOV120101, is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity. HM781-36B irreversibly inhibits EGFR (HER1 or ErbB1), including EGFR mutants, HER2, and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. EGFRs, cell surface receptor tyrosine kinases, are often upregulated in a variety of cancer cell types and play key roles in cellular proliferation and survival.
Synonym: HM781-36B; HM78136B; HM-78136B; HM 78136B; NOV120101; NOV-120101; NOV 120101; Poziotinib
IUPAC/Chemical Name: 1-(4-((4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one
SMILES Code: C=CC(N1CCC(OC2=CC3=C(NC4=CC=C(Cl)C(Cl)=C4F)N=CN=C3C=C2OC)CC1)=O
1: Cha MY, Lee KO, Kim M, Song JY, Lee KH, Park J, Chae YJ, Kim YH, Suh KH, Lee GS, Park SB, Kim MS. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012 May 15;130(10):2445-54. doi: 10.1002/ijc.26276. Epub 2011 Aug 24. PubMed PMID: 21732342.
2: Nam HJ, Kim HP, Yoon YK, Hur HS, Song SH, Kim MS, Lee GS, Han SW, Im SA, Kim TY, Oh DY, Bang YJ. Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Lett. 2011 Mar 28;302(2):155-65. PubMed PMID: 21306821.
